Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701748 | 1.00 | ADORA3 (0.33) | ADORA3ALDH1A1L3MBTL1PPARGPPARA | |
| SCHEMBL700952 | 1.00 | ADORA3 (0.33) | ADORA3ALDH1A1L3MBTL1PPARGPPARA | |
| SCHEMBL8643561 | 0.79 | MMP8 (0.33) | — | |
| SCHEMBL9350164 | 0.79 | ADORA3 (0.34) | ADORA3ALDH1A1PPARGPPARA | |
| SCHEMBL9514143 | 0.79 | ADORA3 (0.34) | ADORA3ALDH1A1PPARGPPARA | |
| SCHEMBL2327536 | 0.79 | ADORA3 (0.34) | ADORA3ALDH1A1PPARGPPARA | |
| SCHEMBL6741779 | 0.74 | PPARG (0.51) | ALDH1A1PPARGPPARA | |
| SCHEMBL16754032 | 0.74 | PPARG (0.51) | ALDH1A1PPARGPPARA | |
| SCHEMBL8649495 | 0.74 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1PPARA | |
| SCHEMBL29163122 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-6653305-B2 | For therapy of tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-25 | — | — | US | disclosed |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ADORA3 2373/4885ALDH1A1 142/4885L3MBTL1 4797/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ADORA3 2373/4885ALDH1A1 142/4885L3MBTL1 4797/4885 |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | ADORA3 2816/4885ALDH1A1 300/4885L3MBTL1 4804/4885 |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, CYP11B2 | ADORA3 1260/4885ALDH1A1 2095/4885L3MBTL1 3744/4885 |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | ADORA3 263/4885ALDH1A1 175/4885L3MBTL1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.